Illinois Featured Content

  • Unprecedented compound takes a step toward breast cancer clinical trials

    Nov 27, 2023 10:30 am by Jonathan KingInnovation
    Cancer Center at Illinois (CCIL) researchers David Shapiro and Paul Hergenrother

    Images

    • Cancer Center at Illinois (CCIL) researchers David Shapiro and Paul Hergenrother

    TEQ103 targets estrogen receptor alpha (ERα) positive breast cancer cells and kills only the cells with an activated stress response, the so-called a-UPR.